Breaking 340B: What Happens After Medicare Payment Cut?
CMS’ reduced payment for drugs purchased at 340B prices went into effect January 1 – but still faces potential legal and legislative challenges. But the real question is what will happen if it sticks?
You may also be interested in...
340B Payment Cut Overturned By US Federal Court; What Comes Next?
Siding with coalition of hospitals, judge ruled that HHS lacked authority to cut Medicare reimbursement for drugs purchased at 340B prices. That should change the dynamics of the 340B reform debate heading into 2019 – but don’t expect the Trump Administration to back down on its push to rein in what it sees as abuses of the discount.
US Reimbursement Briefs: Medicare Payments For New Drugs; 340B Rules; HHS' Best
Recent developments in US federal government regulation of prescription drug pricing and reimbursement.
Pharma’s Blame-The-Middleman Strategy Pays Off – For Now
Success of drug industry’s campaign to highlight role of 'middlemen' in the supply chain was never more clear than during President Trump’s Rose Garden drug pricing event. But what happens now that the attention is turned squarely back on manufacturers?